BRIEF-Larimar Therapeutics Announces Positive Initial Data From Ongoing Long-Term Open Label Extension Study

Reuters
16 Dec 2024

Dec 16 (Reuters) - Larimar Therapeutics Inc :

* LARIMAR THERAPEUTICS ANNOUNCES POSITIVE INITIAL DATA FROM ONGOING LONG-TERM OPEN LABEL EXTENSION STUDY & PROGRESS ACROSS NOMLABOFUSP PROGRAM FOR FRIEDREICH’S ATAXIA

* LARIMAR THERAPEUTICS INC - NOMLABOFUSP 25 MG WELL TOLERATED IN 14 PARTICIPANTS FOR UP TO 260 DAYS

* LARIMAR THERAPEUTICS INC - BLA SUBMISSION TARGETED FOR 2H 2025 FOR POTENTIAL ACCELERATED APPROVAL

* LARIMAR THERAPEUTICS INC: PROJECTED RUNWAY INTO Q2 OF 2026

Source text: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10